Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Guindo Chirfi

Li Dean Y

Zachary Jennifer

Williams David Michael

DeLuca Richard R.

Oosthuizen Johannes Jacobus

Davis Robert M

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

Swing & day trader
Tweets are my opinion only and not a recommendation to buy or sell any security.
I don't Have any subservice/ WhatsApp group /Telegram group!

HODOR

Former scientist at a major biotech for 15+ yrs, now I trade stocks daily. Tweets are for entertainment only - not investment advice.

Founder SELLTHESPIKE CAFL Stockmarket Trading Investing  TrainTheEye Options Stocks Cars 97%biz/3% jokes Know your limit$ JDMBABroker Learn 2 think for yourself

Maliboooooom !

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Marty Chargin

Teaching traders how to trade with conviction.

Flow Education @ BullFlow https://t.co/iWqwhYLiqb
Live Trading @ Stock Talk Insiders https://t.co/8mopfzD9l9

Merck & Company Inc (MRK) Stock Price, Analysis & Trade Signals